IP Library Granted Patent US 8,624,031
Granted Patent B2
US 8,624,031 · App. 13/606,370 · Granted Jan 7, 2014

Production of alkaloids without the isolation of intermediates

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,624,031
App. No.
13/606,370
Granted
Jan 7, 2014
Kind
B2
Abstract

The invention relates to processes for the production of alkaloids without the isolation of intermediates.

Claims (20)

1. A process for producing a compound comprising Formula (II) or salt thereof, the process comprising:

a. contacting a compound comprising Formula (I) with a ring forming agent and a proton donor to form a compound comprising Formula (V);

b. contacting the compound comprising Formula (V) with R 16 OCOX to form a compound comprising Formula (VI); and

c. contacting the compound comprising Formula (VI) with an hydrolysis agent to form the compound comprising Formula (II) according to the following reaction scheme:

wherein no intermediates are isolated and,

R 1 , R 2 , R 3 , R 5 , R 8 , and R 8′ are independently chosen from hydrogen, hydrocarbyl, substituted hydrocarbyl, halogen, and {—}OR 15 ;

R 4 is {—}OR 15 ;

R 6 , R 7 , R 16 , and R 17 are independently chosen from hydrogen, hydrocarbyl and substituted hydrocarbyl;

R 14 is chosen from hydrogen, and {—}OR 15 ;

R 15 is chosen from hydrogen, hydrocarbyl, and substituted hydrocarbyl; and

X is chosen from fluorine, chlorine, bromine, and iodine.

2. The process of claim 1 , wherein R 3 is alkyl or alkoxy; and R 6 , R 7 , R 16 , and R 17 are independently alkyl or substituted alkyl.

3. The process of claim 1 , wherein the ring forming agent is an orthoester chosen from an orthoformate and an orthoacetate; the proton donor has a pKa of less than about 6; and step (a) is conducted in the presence of a polar organic solvent and at a temperature from about 40° C. to about 80° C.

4. The process of claim 1 , wherein R 16 is methyl, ethyl, or propyl; X is chlorine or bromine; and step (b) is conducted at a temperature from about 0° C. to about 100° C.

5. The process of claim 1 , wherein the hydrolysis agent is a proton acceptor having a pKa greater than about 7; and step (c) is conducted at a temperature from about 60° C. and about 140° C.

6. The process of claim 1 , wherein further comprising at least one solvent extraction step to yield an aqueous phase and an organic phase, the organic phase containing the reaction product.

7. The process of claim 1 , wherein R 1 , R 2 , R 5 , R 8 , R 8′ , R 14 and R 15 are hydrogen; R 3 is {—}OCH 3 ; R 6 , R 7 , and R 17 are methyl; the ring forming agent is trimethyl orthoformate; the molar ratio of the compound comprising Formula (I) to trimethyl orthoformate is about 1:2; the proton donor is methane sulfonic acid; step (a) is conducted in the presence of methanol and acetonitrile as a solvent and at a temperature of 60-65° C. to yield a reaction mixture containing the compound comprising Formula (V); the reaction mixture containing the compound comprising Formula (V) is extracted with toluene to obtain an organic phase containing the compound comprising Formula (V); to the organic phase containing the compound comprising Formula (V) is added the compound comprising R 16 OCOX, wherein R 16 is ethyl and X is chlorine; the molar ratio of the compound comprising Formula (I) to the compound comprising R 16 OCOX is about 1:0.5; step (b) is conducted at a temperature of 60-65° C. to yield a reaction mixture containing the compound comprising Formula (VI); the reaction mixture containing the compound comprising Formula (VI) is extracted with water to obtain an organic phase comprising the compound comprising Formula (VI); to the organic phase comprising the compound comprising Formula (VI) is added sodium hydroxide as the hydrolysis agent, and a solvent mixture of dimethylsulfoxide and 1,2-propyldiol; step (c) is conducted at a temperature of about 120° C.; and the compound comprising Formula (II) or salt thereof has a yield of at least 40%.

8. The process of claim 1 , wherein the C-5, C-9, C-13, and C-14 stereocenters of the compound comprising Formula (II) or the salt thereof are chosen from RRRR, RRRS, RRSR, RRSS, RSRS, RSRR, RSSR, RSSS, SRRR, SRRS, SRSR, SRSS, SSRS, SSRR, SSSR, and SSSS, respectively.

9. The process of claim 1 , further comprising contacting the compound comprising Formula (II) or salt thereof with a hydrolysis agent to form a compound comprising Formula (III) or salt thereof:

wherein R 1 , R 2 , R 3 , R 5 , R 8 , R 8′ , and R 14 are as defined in claim 1 .

Assignments (13)
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 31, 2025
From: SPECGX LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 072313/0063 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →
RELEASE OF SECURITY INTEREST Recorded Jun 17, 2022
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS, INC.; MALLINCKRODT LLC; MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY); SPECGX LLC; STRATATECH CORPORATION; VTESSE LLC (F/K/A VTESSE INC.)
Reel/Frame 060389/0839 →
SECURITY INTEREST Recorded Dec 10, 2019
From: MALLINCKRODT ARD IP LIMITED; MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED; SPECGX LLC; OCERA THERAPEUTICS, INC.; MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY; STRATATECH CORPORATION; VTESSE INC.; MALLINCKRODT LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 051256/0829 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2017
From: MALLINCKRODT LLC
To: SPECGX LLC
Reel/Frame 044891/0376 →
SECURITY INTEREST Recorded Mar 19, 2014
From: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS INC.; MALLINCKRODT CARIBBEAN, INC.; MALLINCKRODT US POOL LLC; MALLINCKRODT INC.; LUDLOW CORPORATION; CNS THERAPEUTICS, INC.; ENTERPRISES HOLDINGS, INC.; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS, INC; MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC; MALLINCKRODT ENTERPRISES HOLDINGS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 032480/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 10, 2012
From: WANG, PETER X.; JIANG, TAO; BERBERICH, DAVID W.
To: MALLINCKRODT LLC
Reel/Frame 028924/0315 →